In the present study, the fact that the SGLT-2/1 selectivity of canagliflozin is lower than that of other SGLT-2 inhibitors might have affected the results, especially in patients with obesity and T2DM32,35,41. This evidence concerns the gene SLC5A2 and obesity disorder.